Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
How ‘GLP-1 Friendly’ Claims Are Regulated in the UK and EU
Weight‑loss drugs targeting the GLP‑1 pathway are reshaping consumer demand for smaller, nutrient‑dense portions, prompting food manufacturers to explore “GLP‑1 friendly” labeling. In the EU, such phrasing is classified as a health claim and, without an approved application, is unlikely to receive authorization. The UK restricts disease‑related claims and bans advertising of GLP‑1 medicines, but has not yet ruled on “GLP‑1 friendly” food claims, leaving a regulatory gray area. Consequently, brands must ensure claims are accurate and non‑misleading to avoid potential enforcement.
Gene Therapy Poised to Redefine Obesity Treatment Landscape
1/GLP-1 obesity and weight-loss drugs - such as $NVO Ozempic & Wegovy and $LLY Zepbound & Mounjaro have long become a household name - making Obesity the fastest growing market in the BioTech and Pharma ecosystem and generating unprecedented revenues....
Your Vitamin D Levels in Midlife Could Shape Your Brain Decades Later
A 16‑year longitudinal study of 793 middle‑aged adults found that higher vitamin D levels in their 30s‑40s were associated with lower tau protein accumulation later, a biomarker linked to Alzheimer’s disease. Participants with vitamin D above 30 ng/mL showed reduced tau...
NHS England on Digital-by-Default, EPR Adoption, Optimisation, Improving Workflows
NHS England reports steady progress toward a digital‑by‑default NHS, with most trusts now running electronic patient records (EPRs) and central data repositories. High‑performing trusts are 8% more productive per pound, achieve a 4% shorter length of stay, and meet referral...
Major Upgrade for Musgrove Park Hospital’s Nuclear Medicine Department
Musgrove Park Hospital in Somerset has reopened its Nuclear Medicine department after a comprehensive refurbishment that includes a brand‑new SPECT/CT scanner. The state‑of‑the‑art equipment merges nuclear imaging with diagnostic‑quality CT, delivering high‑resolution 3‑D images for precise diagnosis and treatment planning....
‘Humble’ AI Reveals When It Is Uncertain in Diagnoses
MIT researchers unveiled BODHI, a “humble” AI framework that forces large language models to explicitly signal uncertainty in clinical diagnoses. The system implements six integrated steps and a two‑pass chain‑of‑thought prompting that separates internal reasoning from the clinician‑facing response. In...
Akeso Reports P-Ib/II Trial Data on Cadonilimab Combination to Treat NSCLC
Akeso presented Phase Ib/II data on its cadonilimab combination with anlotinib and docetaxel in patients whose advanced non‑small cell lung cancer (NSCLC) progressed after PD-(L)1 inhibitor therapy. At a median follow‑up of 21.5 months, the regimen achieved a 6‑month progression‑free...
BioNTech to Shutter Singapore HQ After 'Comprehensive Review'
BioNTech announced it will close its Singapore headquarters, a manufacturing site it purchased from Novartis in 2020. The Tuas Biomedical Park facility, which employs roughly 200 staff, will be shuttered as part of a comprehensive operational review. The decision reflects...
DDW Highlights: 7 April 2026
In this episode, Bruno Quinney highlights several breakthrough developments in drug discovery: the FDA’s accelerated approval of Avlaya, the first brain‑penetrant biologic for Hunter syndrome; Eli Lilly’s $2 billion acquisition of Centessa Pharmaceuticals to expand its orexin‑based sleep‑wake therapies; Mount Sinai’s AI‑powered...
£1.5 Million NIHR Funds Innovations at Leeds Teaching Hospitals
The National Institute for Health and Care Research has awarded Leeds Teaching Hospitals £1.5 million (about $1.9 million) to accelerate four priority projects, including AI‑driven imaging algorithms, a non‑invasive histotripsy platform for cancer therapy, a simulated surgical suite for greener operations, and...
World Health Day FAQ: How Global Science Is Having Clinical Impact
World Health Day 2026 spotlights a wave of global partnerships that are turning research breakthroughs into everyday clinical care. AI‑driven bioinformatics platforms from MD Anderson and SOPHiA Genetics are converting complex genomics into bedside decision tools, while collaborations such as...
Dr. Kaeberlein's Optispan Podcast Series - Rapamycin and More
AI modeling compares 6 mg rapamycin taken with grapefruit juice versus berberine 1000 mg daily. Grapefruit juice irreversibly destroys intestinal CYP3A4 and P‑gp, boosting rapamycin AUC 3‑4× and Cmax 2.5‑3.5×, effectively tripling the dose for up to three days. Berberine provides reversible...
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
President Trump’s FY 2027 budget proposes a $7.23 billion allocation for the FDA, a 3.2% increase over 2026, while the broader HHS budget shrinks by 12%. The agency plans to make the rare pediatric disease priority‑review voucher program permanent, averting an estimated...
Sanofi's Bispecific Lunsekimig Has Mixed Readouts in Phase 2
Sanofi reported mixed phase 2 results for its bispecific antibody lunsekimig, which targets IL‑13 and TSLP. The drug met primary endpoints in the AIRCULES asthma trial and the DUET study for chronic rhinosinusitis with nasal polyps, showing reduced exacerbations and improved...
Humanity and Excellence Thrive Together in Supportive Healthcare Cultures
If you work in medicine, you know the feeling of being asked to deliver more while the system quietly strips away the humanity required to do the job well. That is what makes this episode of The Podcast by KevinMD worth...
Sanofi Bispecific Sails Through Asthma, Sinusitis Trials, but Disappoints in Eczema
Sanofi announced mixed mid‑stage results for its bispecific nanobody aimed at treating multiple immune‑mediated diseases. The drug achieved its primary endpoints in Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps, demonstrating clinically meaningful improvements. Conversely, the same molecule...
Organogenesis Reports Trial Results on PuraPly AM for Wound Healing in Diabetic Foot Ulcers
Organogenesis completed a 170‑patient randomized trial of PuraPly AM, an antimicrobial collagen matrix, versus standard of care for non‑healing diabetic foot ulcers. The study met its primary endpoint, showing significantly higher wound‑closure rates at 12 weeks. PuraPly AM integrates cross‑linked...
UCLA Receives $33 Million Grant to Combat Los Angeles Youth Mental‑Health Crisis
UCLA has been awarded a $33 million grant from the Ballmer Group to launch three campuswide initiatives that will expand youth mental‑health training and services across Los Angeles. The funding targets a critical shortage of qualified professionals and aims to boost the...
American Heart Association Issues New Plant‑Forward Dietary Guidance
The American Heart Association has released updated dietary guidance that emphasizes vegetables, fruits, whole grains, olive oil and plant‑based proteins while urging a cutback on saturated fat. The shift aims to give clinicians a clearer framework for heart‑health counseling amid...
BCL-2 and Cellular Senescence in Pulmonary Fibrosis
Researchers identified BCL-2 as a key blocker of fibroblast apoptosis in idiopathic pulmonary fibrosis (IPF). Conditional over‑expression of BCL‑2 in PDGFRα‑positive fibroblasts generated senescent, pro‑fibrotic myofibroblasts that persisted in mouse lungs. Spatial transcriptomics confirmed BCL‑2‑positive senescent myofibroblasts in human IPF...
Brain Cells Identified as Key Drivers of Exercise Endurance, Opening Door to New Therapies
Scientists at UT Southwestern Medical Center and the University of Pennsylvania have identified ventromedial hypothalamic SF1 neurons that program endurance capacity in mice. Published in Neuron, the work suggests a neural target for therapies that could mimic exercise benefits when...
Metformin Raises Exercise‑Mimetic Metabolite in Prostate Cancer Patients
Researchers at the Sylvester Comprehensive Cancer Center reported that metformin elevates N‑lactoyl‑phenylalanine (Lac‑Phe), a molecule that spikes after intense exercise, in men undergoing hormone therapy for prostate cancer. The finding, published in EMBO Molecular Medicine, suggests a drug‑based route to...
Pfizer, BioNTech Drop Updated COVID‑19 Vaccine Study After Low Enrollment
Pfizer and BioNTech have scrapped a late‑stage trial of an updated COVID‑19 vaccine for adults aged 50‑64 because enrollment fell short of FDA‑required numbers. The move highlights the difficulty of conducting large‑scale studies in a post‑pandemic market and comes as...
Medvi’s $401 M Revenue Surge Shadowed by Fake Doctor Ads Probe
Medvi, an AI‑powered telehealth startup, posted $401 million in revenue and $65 million profit last year and projects $1.8 billion in sales this year. The company now faces FTC and FDA scrutiny after investigations uncovered affiliate‑driven ads that feature non‑existent doctors and AI‑generated...
UPAR Targeting to Enable CAR T Cell Therapies to Treat Solid Cancers
Researchers at Memorial Sloan Kettering demonstrated that CAR T cells engineered to target the urokinase plasminogen activator receptor (uPAR) can eradicate solid‑tumor cells and metastases in multiple preclinical models. uPAR was found elevated in 12 of 14 examined cancer types,...
Gallup Poll Shows Health Insurance Premiums Now Top Concern for One‑third of Americans
A Gallup poll released in March finds that roughly one‑third of U.S. adults now list health‑insurance premiums as their top domestic concern. The survey highlights that 3 million people have already lost coverage and estimates up to 10 million could be uninsured...
Bangladesh Launches Emergency Measles‑rubella Drive Targeting 1.2 Million Children After 100 Deaths
Bangladesh has begun an emergency measles‑rubella vaccination campaign aimed at more than 1.2 million children aged six months to five years, after a fast‑moving outbreak that has claimed over 100 lives, mostly children. The effort, coordinated with WHO, UNICEF and Gavi,...
Apnimed Obtains up to $150m in Funds for Commercial Launch of AD109
Apnimed secured a senior secured credit facility of up to $150 million from HealthCare Royalty Partners to fund the commercial readiness and potential U.S. launch of AD109, an oral therapy for obstructive sleep apnea. The deal provides an initial $50 million at...
AI‑Written Code Beats Human Teams in Predicting Preterm Birth, Shaking Up Biomedical Big Data
Researchers at UCSF used large language models to generate code that predicted gestational age and preterm‑birth risk from massive biomedical datasets, matching or surpassing expert‑written analyses. The finding highlights how AI can democratize big‑data analytics in health research.
World Health Day 2026: Quotes that Stand with Science
World Health Day 2026 spotlights the theme “Together for health, Stand with science,” emphasizing evidence‑based decision‑making across public health, policy, and drug discovery. Jeanne Marrazzo warns that declining vaccination rates have reignited measles outbreaks, underscoring a trust gap fueled by misinformation....
Generare Bags $21.6m for Nature-Derived Drug Leads
Paris‑based biotech Generare closed a €20 million Series A to expand its nature‑derived compound library. The company claims it uncovered more than 200 previously unknown microbial small molecules in 2025, outpacing the rest of the field combined. Generare’s platform scans microbial genomes,...
How Many GLP-1 Users Must Seek Medical Care for Side Effects?
Recent Phenomix and Mayo Clinic data reveal that 50‑60% of GLP‑1 users experience significant side effects, far higher than earlier estimates. About 10% of patients incur $5,000 in out‑of‑pocket expenses, while many spend roughly $1,000 managing symptoms. The high cost...
STAT+: Merck’s Experimental HIV Prevention Pill Could Be Made for Less than $5 a Year, Researchers Say
Merck’s experimental HIV‑prevention pill MK 8527 could be manufactured for less than $5 per patient annually, according to a recent cost‑analysis. The drug is in two late‑stage clinical trials that will report efficacy data in the second half of 2027. Earlier...
Identification of Nutritional Risk Factors and Construction of a Nomogram Prediction Model in AIDS Patients
A 2026 study of 110 AIDS patients identified low body mass index, low CD4⁺ T‑lymphocyte count, and low serum albumin as independent nutritional risk factors. Using these three routinely measured variables, the authors built a nomogram that achieved an area...
Ultrasound- and Circumference-Based Quadriceps Mass Is an Independent Predictor of 28-Day Mortality in Critically Ill Patients
A prospective study of 603 ICU patients found that bedside measurements of quadriceps muscle – both circumference and ultrasound thickness – independently predict 28‑day mortality. Higher quadriceps circumference (QC) and greater ultrasound‑derived thickness under minimal (QT‑min) and maximal (QT‑max) transducer...
Bootstrapped Cryo‑AI: LLMs Power Life‑Saving Freeze Tech
Meet Dr. Mark Woodward, undergrad and grad from Stanford, PhD from Harvard, Many years at Google as part of Google brain. One day he realizes that we need the enabling technology to pause biological time for patients that are about...
The Hidden Bottleneck in Digital Healthcare: Why Hospital Wireless Networks Are Under Pressure in 2026
Hospital wireless networks are hitting a critical bottleneck as AI‑driven diagnostics, IoMT devices, and mobile clinical workflows surge. Global AI spending in healthcare is expected to climb to $30.9 billion by 2029, generating data volumes that legacy Wi‑Fi cannot reliably handle....
Amgen Scores with New Thyroid Eye Disease Formulation
Amgen’s Tepezza, the only FDA‑approved therapy for thyroid eye disease, generated about $1.9 billion in 2023 but its IV dosing schedule has limited broader adoption. The company has developed a subcutaneous formulation delivered twice weekly via a wearable injector, aiming to...
New CAR-T Approach May Extend Osteosarcoma Survival
Researchers at Case Western Reserve University and University Hospitals have engineered a novel CAR‑T cell therapy, OSM CAR‑T, that targets oncostatin M receptors on osteosarcoma cells. Preclinical experiments demonstrated potent in‑vitro killing and significant tumor burden reduction in multiple mouse...
AI Turns Patients Into Self‑Diagnosing Symptom Spirals
The ChatGPT Symptom Spiral: when ChatGPT tries to convince you that something is wrong with your medical record or lab results. We have to get used to dealing with patients getting into such troubles, because patients have always tried to...
AI Halves MRI Scan Time with Synthetic Image Interpolation
A new AI software that essentially fills in the blanks between image slices with synthetic images, enables 2x MRI acceleration ! 👇 “Scans of the abdomen that previously took around 23 minutes now are finished within just nine minutes.” 👏...
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
Silo Pharma’s shares surged 51.8% to $0.54 in pre‑market trading after the European Patent Office issued a Rule 71(3) communication indicating a likely grant of a patent for its novel 5‑HT4 receptor preventative therapy. The announcement sparked a broader pre‑market rally...
Microdosing Lacks Scientific Validity and Therapeutic Effect
What does 'microdosing' even mean in this context? It is likely to have no therapeutic effect at all. You might as well just drop it in the ocean. This is not a scientific valid strategy.
Ultra-Endurance Running May Speed Up Aging, RBC Damage
Ultra-Endurance Running May Accelerate Aging and Breakdown of Red Blood Cells | @ASH_hematology https://t.co/aYbsblfTwZ https://t.co/NYSKw0843c
Beyond Automation: Why Human Expertise Still Trumps Software in Complex Dental Billing
Dental billing software and AI tools have streamlined routine claim processing, but they fall short on complex cases that require nuanced judgment. Human specialists can interpret carrier‑specific rules, craft targeted appeals, and detect systemic denial patterns that automation misses. Over‑reliance...
The Challenge Ahead
The Brownstone Institute’s latest post frames the post‑COVID era as a turning point for the medical‑freedom movement, arguing that Big Pharma’s reach now permeates government, academia, and media. It cites Pfizer’s abandonment of its Covid‑shot trial due to recruitment failures...
Why Am I Watching People Get Their Medical Results?
A 2016 congressional law requiring providers to deliver complete medical records electronically took effect in 2021, giving patients instant access to raw test results. This transparency has sparked a new genre of social‑media videos where individuals broadcast their real‑time reactions...
Sovato’s New CEO Explains the Plan to Scale Telesurgery and Take It Worldwide
Sovato has appointed former Intuitive executive Brian Miller as CEO to accelerate its telesurgery platform worldwide. Miller argues that surgeon shortages, geographic variability in outcomes, and proven remote‑surgery technology create a ripe market. Sovato’s strategy focuses on integrating with large...
Can I Opt Out of Having My Doctor Take Notes With AI?
Family physicians are increasingly adopting AI-powered notetaking tools that listen to patient conversations and generate visit summaries within seconds. Cleveland Clinic doctor Eric Boose reports that the technology lets him focus on face‑to‑face interaction, reduces charting time, and lets him...
Allergan Aesthetics Finds Its Next Growth Engine in GLP-1s
Allergan Aesthetics presented new data at the 2026 AAD meeting linking the surge in GLP‑1 weight‑loss drug use to a growing demand for facial aesthetic treatments. A survey of U.S. clinicians showed that 52% of patients on GLP‑1 agonists express...